StreetSmart Live! Presents Frank Holmes’ Virtual Junior Mining Expo on 11/12/2020. Learn More

Streetwise Biotech / Pharmaceuticals Articles

FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients
Source: Streetwise Reports  (9/21/20)
Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress. More >

Biopharma Advances Development of Psilocybin-Based Therapeutics
Source: Streetwise Reports  (9/21/20)
Revive Therapeutics provides an update on its psychedelics therapeutics programs. More >

Pharma Greenlighted to Continue Multinational COVID-19 Study
Source: Streetwise Reports  (9/18/20)
This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial. More >

Expanded Access Protocol for Compassionate Use Approved for Patients with Severe COVID-19
Source: Streetwise Reports  (9/17/20)
Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data. More >

Sorrento Receives FDA Clearance to Proceed with Phase 1 COVID-19 Neutralizing Antibody Trial
Source: Streetwise Reports  (9/17/20)
Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients. More >

Further Trial Data Analyses 'Reinforce' Profile of Biopharma's Multiple Sclerosis Drug
Source: Streetwise Reports  (9/16/20)
The confirmatory results concerning Immunic's lead drug candidate IMU-838 are presented in an H.C. Wainwright & Co. report. More >

Arrowhead Shares Point Higher on Positive Interim Data in Phase 2 Liver Disease Trial
Source: Streetwise Reports  (9/16/20)
Shares of Arrowhead Pharmaceuticals traded 48% higher after the firm reported positive interim results from its Phase 2 study of ARO-AAT in patients with alpha-1 antitrypsin deficiency liver disease. More >

Marinus Pharma Shares Sail 50% Higher on Phase 3 Genetic Epilepsy Trial Results
Source: Streetwise Reports  (9/15/20)
Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy. More >

Immunomedics' Shares Double on Gilead's $21 Billion Buyout Offer
Source: Streetwise Reports  (9/14/20)
Shares of Immunomedics Inc. traded 100% higher after the company reported that it has agreed to be acquired by Gilead Sciences for $88 per share in cash. More >

Life Sciences Company Posts Record Q3 Revenue Due to Successful Recurring Purchase Model
Source: Streetwise Reports  (9/9/20)
Avivagen Inc. reported unaudited financial results for Q3/20 that included record revenue and product sales volumes that nearly eclipsed FY/19 levels. More >

Intra-Cellular Shares Soar on Positive Bipolar Depression Study Findings
Source: Streetwise Reports  (9/9/20)
Shares of Intra-Cellular Therapies traded 77% higher after the company reported that positive data from its Phase 3 Study 402 will form the basis for its sNDA for lumateperone in treating bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy. More >

Trillium Shares Get Boost from Dose Escalation Trial Data and Pfizer's $25 Million Equity Investment
Source: Streetwise Reports  (9/9/20)
Trillium Therapeutics shares traded 37% higher after the company reported updated results from its ongoing TTI-622 and TTI-621 Dose Escalation Studies along with a $25 million equity investment from Pfizer Inc. More >

Biopharma Achieves 'Big Phase 3 Win' for its Pediatric Intrahepatic Cholestasis Drug
Source: Streetwise Reports  (9/9/20)
The recent study results of Albireo Pharma's lead therapeutic candidate are discussed in an H.C. Wainwright & Co. report. More >

Biotech Partners with University to Evaluate Psilocybin for Treating Methamphetamine Use Disorder
Source: Streetwise Reports  (9/4/20)
Revive Therapeutics reported it has entered into clinical trial agreement with the University of Wisconsin-Madison to evaluate the use of psilocybin for the treatment of methamphetamine use disorder. More >

Life Sciences Firm Gains Protocol Approval for Phase 3 COVID-19 Study
Source: Streetwise Reports  (9/2/20)
Revive Therapeutics reported that a renowned independent institutional review board has approved its proposed Phase 3 clinical trial protocol for Bucillamine in COVID-19. More >

Aimmune Therapeutics Shares Soar on Nestlé Health Science's $2.6 Billion Buyout
Source: Streetwise Reports  (8/31/20)
Aimmune Therapeutics shares traded 170% higher after the company reported it entered into a definitive agreement to be acquired by Nestlé for $34.50 per share in cash. More >

Firm Submits Clinical Protocol for IRB Approval for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (8/28/20)
Revive Therapeutics reported it submitted the clinical protocol for independent Institutional Review Board approval for its Phase 3 study of Bucillamine in COVID-19. More >

VBI Shares Climb 34% After Identifying Two One-Dose COVID-19 Vaccine Candidates
Source: Streetwise Reports  (8/27/20)
VBI Vaccines shares traded higher after the company reported preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines. More >

CytoDyn Receives the UK's MHRA Approval for Phase 3 COVID-19 Study
Source: Streetwise Reports  (8/24/20)
CytoDyn Inc. shares traded higher after the company reported it received authorization from the U.K.'s MHRA to proceed with its Phase 3 study of leronlimab in patients with severe-to-critical COVID-19. More >

CureVac Shares Rise on Talks with EC to Supply 405 Million mRNA-Based COVID-19 Vaccine Doses
Source: Streetwise Reports  (8/20/20)
CureVac NV shares traded 13% higher after the company reported it is in advanced discussions with the European Commission to supply up to 405 million doses of a potential mRNA-based COVID-19 vaccine. More >

Biotech Releases Positive Interim Results from Cystic Fibrosis Study
Source: Streetwise Reports  (8/19/20)
This and other recent key events of AzurRx BioPharma are recapped in a ROTH Capital Partners report. More >

California Biopharma to be Acquired by Sanofi for $3.6 Billion
Source: Streetwise Reports  (8/19/20)
The deal is summarized and Principia Biopharma's Q2/20 clinical achievements are recapped in an H.C. Wainwright & Co. report. More >

Momenta Pharmaceuticals Shares Rise 69% on $6.5 Billion Johnson & Johnson Takeover Bid
Source: Streetwise Reports  (8/19/20)
Shares of Momenta Pharmaceuticals set a new 52-week high after the company reported it entered into a definitive agreement with Johnson & Johnson to be acquired for $52.50 per share in cash. More >

Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial
Source: Streetwise Reports  (8/17/20)
Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2. More >

Canadian Biotech Advances Antibodies, Diagnostics Programs in Q2/20
Source: Streetwise Reports  (8/14/20)
One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test. More >

Showing Results: 26 to 50 of 1244 Prev Next

Notable Quotes

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe